'Rezurock' for cGVHD can be prescribed at 'Big 5' hospitals
By Eo, Yun-Ho | translator Hong, Ji Yeon
25.04.02 05:06:01
가나다라
0
A new treatment option with selective ROCK2 inhibitory mechanism
An alternative for patients failing first·second-line treatments…whether it will be approved for reimbursement listing gains attention
▲Product photo of Rezurock
'Rezurock,' a treatment for chronic graft-versus-host disease (cGVHD), is now being prescribed in general hospitals.
According to industry sources, Sanofi Korea's ROCK2 inhibitor Rezurock (belumosudi) has passed the drug committees (DC) of the 'Big 5' tertiary general hospitals, including Samsung Medical Center, Seoul National University Hospitals, Seoul St. Mary's Hospital, Asan Medical Center in Seoul, Sinchon Severance Hospital, as well as medical institutes, including Korea University Anam Hospital, Seoul National University Bundang Hospital, Ulsan University Hospital, and Chonnam National University Hwasun Hospital.
Rezurock is the process of reimbursement listing. Getting listed wi
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)